CN106038544A - Application of composition of Artalbic acid derivatives in preparation of anti-rhinitis drugs - Google Patents
Application of composition of Artalbic acid derivatives in preparation of anti-rhinitis drugs Download PDFInfo
- Publication number
- CN106038544A CN106038544A CN201610405175.XA CN201610405175A CN106038544A CN 106038544 A CN106038544 A CN 106038544A CN 201610405175 A CN201610405175 A CN 201610405175A CN 106038544 A CN106038544 A CN 106038544A
- Authority
- CN
- China
- Prior art keywords
- rhinitis
- compositions
- application
- compound
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/12—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses application of a composition of Artalbic acid O-(benzimidazolyl)ethyl and O-(dihydroxyethylamine)ethyl derivatives in anti-rhinitis drugs and relates to the field of organic composition and medicinal chemistry, in particular to a composition of Artalbic acid O-(benzimidazolyl)ethyl and O-(dihydroxyethylamine)ethyl derivatives and its application in the preparation of anti-rhinitis drugs. The invention discloses a composition of Artalbic acid O-(benzimidazolyl)ethyl and O-(dihydroxyethylamine)ethyl derivatives and a preparation method thereof. Pharmacological experiments show that the composition of Artalbic acid O-(benzimidazolyl)ethyl and O-(dihydroxyethylamine)ethyl derivatives is anti-rhinitis and is worthy of the development of anti-rhinitis drugs.
Description
Technical field
The present invention relates to organic synthesis and medicinal chemistry art, be specifically related to compositions, preparation method and its usage.
Background technology
Rhinitis is common clinical and frequently-occurring disease, and the generation of rhinitis is the most relevant with anaphylaxis, belongs to immune inflammation
Category.At present, treatment rhinitis mainly uses the antihistamine drug such as teldane or the antiallergic agent such as tranilast, ketotifen
Thing, these medicines are poor or invalid to chronicity and the recurrent exerbation curative effect of rhinitis.Therefore, definite ingredients, quality controllable and peace
Complete efficient micromolecular compound, in terms of developing treatment of rhinitis medicine, has potential value.
From natural product, find compound or lead compound and carry out structural modification and obtain its derivant, thus obtaining
The potential drug of high-efficiency low-toxicity most has important value.
The compound I that the present invention relates to be one within 2011, deliver (Antonella Maggio et al.,
2011.Artalbic acid,a sesquiterpene with an unusual skeleton from Artemisia
Alba (Asteraceae) from Sicily.Tetrahedron Letters, 52 (2011) 4,543 4545) compound, I
Compound I has been carried out structural modification, it is thus achieved that two new derivant i.e. compound III and compound IV, and use chemical combination
Thing III and compound IV is prepared for compositions, and rhinitis activity anti-to said composition is evaluated, and it has anti-rhinitis and lives
Property.
Summary of the invention
The invention discloses a new compositions, said composition is made up of compound III and compound IV, said composition
The mass percent of middle compound III and compound IV is respectively 15% and 85%.
Compositions disclosed by the invention can make pharmaceutically acceptable salt or pharmaceutically acceptable carrier.
Pharmacodynamic experiment shows, the compositions of the present invention has preferable anti-rhinitis effect.The present invention pharmaceutically can connect
The salt being subject to has same drug effect.
Compositions 10mg/kg oral administration, nose of scratching rat caused by antigen (ovalbumin) and histamine, sneeze are anti-
Answer and nasal cavity vascular permeability raises inhibited, therefore, can be used for the medicine of preparation treatment rhinitis.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by concrete real
Execute any restriction of example, but be defined in the claims.
Detailed description of the invention
The preparation of embodiment 1 compound Artalbic acid
The document that the preparation method of compound Artalbic acid (I) is delivered with reference to Antonella Maggio et al.
(Antonella Maggio et al.,2011.Artalbic acid,a sesquiterpene with an unusual
skeleton from Artemisia alba(Asteraceae)from Sicily.Tetrahedron Letters,52
(2011) 4,543 4545) method.
The synthesis of O-bromoethyl derivant (II) of embodiment 2 Artalbic acid
Compound I (266mg, 1.00mmol) is dissolved in 10mL benzene, in solution, adds tetrabutyl ammonium bromide (TBAB)
(0.08g), glycol dibromide (3.760g, 20.00mmol) and 50% sodium hydroxide solution of 6mL.Mixture is Celsius 40
Degree stirring 16h.After 16h, reactant liquor is poured in frozen water, be extracted twice with dichloromethane immediately, merge organic phase solution.So
Washing organic phase solution 5 times with water and saturated aqueous common salt successively afterwards, then be dried with anhydrous sodium sulfate, last concentrating under reduced pressure is removed
Solvent obtains product crude product.Product crude product silica gel column chromatography purification (flowing is mutually: petroleum ether/acetone=100:1.0, v/v),
Collect brown concentrate elution band and fling to solvent and i.e. obtain the brown ceramic powder (272mg, 73%) of compound II.
1H NMR(500MHz,DMSO-d6)δ11.41(s,1H),6.06(s,1H),5.76(s,1H),4.99(s,1H),
4.71(s,1H),4.56(s,1H),3.86(s,2H),3.54(s,2H),2.65(s,1H),2.43(s,2H),2.33(s,2H),
2.10(s,1H),1.64(s,3H),1.54(s,1H),1.44(s,2H),0.95(s,3H).
13C NMR(125MHz,DMSO-d6)δ201.95(s),175.93(s),149.13(s),148.15(s),117.05
(s),109.43(s),81.86(s),70.27(s),57.68(s),41.26(s),39.07(s),38.86(s),35.69(s),
33.36(s),30.72(s),20.44(s),18.42(s).
HRMS(ESI)m/z[M+H]+calcd for C17H26BrO4:373.1014；found 373.1017.
The synthesis of O-(benzimidazolyl) ethyl derivative (III) of embodiment 3 Artalbic acid
Compound II (187mg, 0.5mmol) is dissolved in the middle of 20mL acetonitrile, be added thereto to Anhydrous potassium carbonate (345mg,
2.5mmol), potassium iodide (84mg, 0.5mmol) and benzimidazole (1180mg, 10mmol), mixture is heated to reflux 2h.Reaction
After end, reactant liquor is poured in frozen water, extract 2 times with equivalent dichloromethane, merge organic facies.Successively with water and saturated common salt
Organic facies after water washing merging, then be dried with anhydrous sodium sulfate, concentrating under reduced pressure is removed solvent and is obtained product crude product.Product is thick
Product silica gel column chromatography purification (flowing is mutually: petroleum ether/acetone=100:1.0, v/v), collects brown and concentrates elution band, concentrate
I.e. obtain the brown solid (80.0mg, 39%) of compound III.
1H NMR (500MHz, DMSO-d6) δ 16.65 (s, 1H), 8.22 (s, 1H), 7.61 (d, J=25.0Hz, 2H),
7.25(s,1H),7.16(s,1H),6.05(s,1H),5.76(s,1H),4.90(s,1H),4.67(s,1H),4.58(s,1H),
4.12(s,1H),4.00(s,1H),3.85(s,2H),2.63(s,1H),2.43(s,2H),2.35(s,2H),1.95(s,1H),
1.61(s,3H),1.52(s,2H),1.37(s,1H),0.94(s,3H).
13C NMR(125MHz,DMSO-d6)δ201.70(s),175.59(s),149.00(s),147.93(s),146.20
(s),139.75(s),133.40(s),123.95(s),123.48(s),118.46(s),116.84(s),110.97(s),
109.08(s),81.62(s),67.86(s),57.36(s),44.96(s),41.15(s),38.72(s),38.62(s),
35.56(s),30.41(s),20.19(s),18.28(s).
HRMS(ESI):m/z[M+H]+calcd for C24H31N2O4:411.2284；found:411.2281.
The synthesis of O-(two hydroxyethylamines) ethyl derivative of embodiment 4 Artalbic acid
Compound II (187mg, 0.5mmol) is dissolved in the middle of 20mL acetonitrile, be added thereto to Anhydrous potassium carbonate (690mg,
5.0mmol), potassium iodide (252mg, 1.5mmol) and diethanolamine (1051mg, 10mmol), mixture is heated to reflux 1h.Reaction
Reactant liquor is poured in 20mL frozen water after end, extract 3 times with equivalent dichloromethane, merge organic facies.Successively with water and saturated
Organic facies after brine It merging, then be dried with anhydrous sodium sulfate, concentrating under reduced pressure is removed solvent and is obtained product crude product.Produce
Thing crude product silica gel column chromatography purification (flowing is mutually: petroleum ether/acetone=100:1.0, v/v), collects yellow and concentrates elution band
And fling to solvent and i.e. obtain the faint yellow solid (146.9mg, 74%) of compound IV.
1H NMR(500MHz,DMSO-d6)δ18.72(s,1H),δ6.11(s,1H),5.80(s,1H),5.14(s,1H),
(4.73 s, 1H), 4.63 (s, 1H), 3.57 (s, 2H), 3.45 (s, 4H), 2.70 (d, J=15.6Hz, 3H), 2.60 (s, 4H),
2.50 (s, 2H), 2.46 (s, 2H), 2.33 (s, 1H), 1.88 (s, 2H), 1.68 (s, 3H), 1.62 (d, J=19.9Hz, 3H),
1.02(s,3H).
13C NMR(125MHz,DMSO-d6)δ202.01(s),176.11(s),149.21(s),148.55(s),117.15
(s),109.60(s),81.93(s),67.25(s),59.28(s),57.88(s),56.83(s),53.74(s),41.36(s),
39.24(s),38.93(s),35.88(s),30.82(s),20.61(s),18.49(s).
HRMS(ESI):m/z[M+H]+calcd for C21H36N1O6:398.2543；found:398.2547.
Embodiment 5 present composition causes the impact of rat allergic rhinitis to ovalbumin
Male SD rat, body weight 180～220g, lumbar injection ovalbumin 1mg and gel aluminum hydroxide 10mg, thereafter every
Day injection 1 time, totally 7 times.Beginning from the 14th day, every day instills 1mg/ml ovalbumin normal saline solution at rat both sides nasal cavity
10ul, totally 7 times.Rat sneeze and the number of times of wiping nose in observing at once 30 minutes after last instillation, trial drug is in white of an egg egg
White last instils and is orally administered to for first 1 hour.
The preparation of compositions: the powder that will cross the 15mg compound III of 200 mesh nets after grinding crosses 200 after grinding
The powder of the 85mg compound IV of mesh net loads in tubule with cover and i.e. obtains 100mg compositions with the mixing of turbine stirring instrument,
Obtain the solution of compositions by the compositions of this 100mg of water dissolution during use.
From table 1, compositions (10mg/kg) substantially suppresses the sneeze of allergic rhinitis rat caused by ovalbumin and scratches
Grab nose reaction.Compound III and compound IV acts on without this.
Table 1 present composition causes the impact of rat allergic rhinitis to ovalbumin
* p < 0.05, compares with matched group
The impact of the rat rhinitis that histamine is caused by embodiment 6 present composition
Male SD rat, body weight 180～220g, it is orally administered to after trial drug 1 hour, both sides nasal cavity instills 1M histamine
Normal saline solution 10ul, rat sneeze and the number of times of wiping nose in observing 30 minutes.
From table 2, the present composition (10mg/kg) significantly reduces the sneeze number of times of rhinitis rat caused by histamine, right
Nose of scratching reacts in suppression trend.Compound III and compound IV acts on without this.
Table 2 present composition causes the impact of rat rhinitis to histamine
* p < 0.05, compares with matched group
Embodiment 7 present composition causes the impact that rat nasal cavity vascular permeability raises to ovalbumin, histamine
Male SD rat, body weight 180～220g, observe ovalbumin and group with active sensitization rat and normal rat respectively
Nasal cavity vascular permeability that amine causes raises, and the method for sensitization of rat is tested with allergic rhinitis, after initial immunity the 14th day,
Rats by intraperitoneal injection pentobarbital sodium 40mg/kg, from trachea to nasal intubation after anesthesia, intubates this and constant flow pump phase after fixing
Even (0.25ml/min0, with 37 DEG C of normal saline flushing nasal cavities 10 minutes, the 1%Evans indigo plant physiology of rat tail vein injection thereafter
Saline solution 5ml/kg, collected perfusate 10 minutes after 3 minutes.At sensitized rats and normal rat, respectively containing ovum in perfusate
Albumin 1mg/ml and histamine 40ug/ml, the perfusate collected from nasal cavity is centrifuged 10 minutes through 1200 × g, and at 620nm, colorimetric is surveyed
Determine the Evans indigo plant concentration in supernatant, test medicine and antigen or first 1 hour oral administration of histamine perfusion.
From table 3, the nose of allergic rhinitis rat caused by the present composition (10mg/kg) substantially suppression ovalbumin
Chamber vascular permeability.Compound III and compound IV acts on without this.
Table 3 present composition causes the impact that rat nasal cavity vascular permeability raises to ovalbumin
* p < 0.01, compares with matched group
From table 4, present composition 10mg/kg substantially reduces the nasal cavity vascular permeability of rat caused by histamine.Change
Compound III and compound IV acts on without this.
Table 4 present composition causes the impact that rat nasal cavity blood flow permeability raises to histamine
* p < 0.01, compares with matched group
Conclusion: composition oral is administered, nose of scratching rat caused by antigen (ovalbumin) and histamine, sneeze react
And nasal cavity vascular permeability raises and has the effect of significantly inhibiting, therefore, can be used for the medicine of preparation treatment rhinitis.Compound III
Rat caused by antigen (ovalbumin) and histamine scratched nose, sneeze reaction and nasal cavity vascular permeability liter with compound IV
Height does not significantly inhibit effect, therefore, is not useable for the medicine of preparation treatment rhinitis.
The preparation of embodiment 6 composition tablet involved in the present invention
Taking 2 grams of compositionss, the customary adjuvant 18 grams of tablet is prepared in addition, and mixing, conventional tablet presses makes 100.
The preparation of embodiment 7 composition capsule involved in the present invention
Taking 2 grams of compositionss, the customary adjuvant such as starch 18 grams of capsule is prepared in addition, mixing, encapsulated makes 100.
Claims (10)
1. a compositions, is characterized by that said composition is made up of compound III and compound IV, compound in said composition
The mass percent of III and compound IV is respectively 15% and 85%,
2. the preparation method of compositions as claimed in claim 1, is characterized by: by powder and the compound IV of compound III
Powder be sufficiently mixed according to mass percent respectively 15% and 85%.
3. a compositions as claimed in claim 1 application in anti-rhinitis medicament thing.
The compositions the most according to claim 3 application in anti-rhinitis medicament thing, is characterized by: described rhinitis is antigen institute
The rhinitis caused.
The compositions the most according to claim 4 application in anti-rhinitis medicament thing, is characterized by: described antigen is white of an egg egg
In vain.
The compositions the most according to claim 5 application in anti-rhinitis medicament thing, is characterized by: described compositions can press down
Scratch caused by ovalbumin processed nose number of times and sneeze reaction.
The compositions the most according to claim 5 application in anti-rhinitis medicament thing, is characterized by: described compositions can press down
The rising of nasal cavity vascular permeability caused by ovalbumin processed.
The compositions the most according to claim 3 application in anti-rhinitis medicament thing, is characterized by: described rhinitis is histamine institute
The rhinitis caused.
The compositions the most according to claim 8 application in anti-rhinitis medicament thing, is characterized by: described compositions can press down
Scratch caused by histamine processed nose number of times and sneeze reaction.
The compositions the most according to claim 8 application in anti-rhinitis medicament thing, is characterized by: described compositions is permissible
The rising of nasal cavity vascular permeability caused by suppression histamine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610405175.XA CN106038544A (en) | 2016-06-08 | 2016-06-08 | Application of composition of Artalbic acid derivatives in preparation of anti-rhinitis drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610405175.XA CN106038544A (en) | 2016-06-08 | 2016-06-08 | Application of composition of Artalbic acid derivatives in preparation of anti-rhinitis drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106038544A true CN106038544A (en) | 2016-10-26 |
Family
ID=57169902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610405175.XA Pending CN106038544A (en) | 2016-06-08 | 2016-06-08 | Application of composition of Artalbic acid derivatives in preparation of anti-rhinitis drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106038544A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105343080A (en) * | 2015-12-07 | 2016-02-24 | 南京海澳斯生物医药科技有限公司 | Composition and application of composition in preparation of medicines for resisting rhinitis |
-
2016
- 2016-06-08 CN CN201610405175.XA patent/CN106038544A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105343080A (en) * | 2015-12-07 | 2016-02-24 | 南京海澳斯生物医药科技有限公司 | Composition and application of composition in preparation of medicines for resisting rhinitis |
Non-Patent Citations (1)
| Title |
|---|
| ANTONELLA MAGGIO,ET AL.: "Artalbic acid, a sesquiterpene with an unusual skeleton from Artemisia alba (Asteraceae) from Sicily", 《TETRAHEDRON LETTERS》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104188980B (en) | O-(morpholinyl) ethyl derivative of Cleistanone Cleistanone, preparation method and its usage | |
| CN104083379B (en) | The dimethylamine derivative of Cleistanthus sumafranus (Miq) Muell-Arg-C. Saichikii Merr wood ketone Cleistanone is preparing the application in anti-rhinitis medicament thing | |
| CN105287598A (en) | Composition and application of composition in medicine for resisting rhinitis | |
| CN104402964B (en) | O-(imidazole radicals) ethyl derivative of Cleistanone, preparation method and its usage | |
| CN106038544A (en) | Application of composition of Artalbic acid derivatives in preparation of anti-rhinitis drugs | |
| CN105998009A (en) | Application of composition of Salviskinone A benzimidazolyl and di(2-methylmercapto ethyl)amido derivatives in anti-rhinitis drugs | |
| CN106038525A (en) | Composition of artalbic acid derivatives in preparation of anti-rhinitis medicines | |
| CN104825468A (en) | Application of cleistanone O-(benzimidazolyl) ethyl derivative in preparation of anti-rhinitis drugs | |
| CN105287568A (en) | Composition and application thereof to rhinitis resistant medicines | |
| CN105343044A (en) | Composition and application thereof in anti-rhinitis drug | |
| CN106074512A (en) | The composition of Ah draw'sing Bick acid triazolyl and 1H tetrazole radical derivative is for preparing anti-rhinitis medicament thing | |
| CN104814967A (en) | Application of cleistanthus sumatranus ketone O-(1H-tetrazole base) ethyl ramification to preparing rhinitis-resisting medicine | |
| CN105343080A (en) | Composition and application of composition in preparation of medicines for resisting rhinitis | |
| CN105250271A (en) | Composition and application of composition in rhinitis-resistant medicine | |
| CN106420713A (en) | Application of Atropurpuran derivative composition in anti-rhinitis drugs | |
| CN105232535A (en) | Composition and application thereof in anti-rhinitis drugs | |
| CN106236750A (en) | The application in anti-rhinitis medicament thing of the derivative composition of Schiglautone A | |
| CN105920011A (en) | Application of composition of tetrahydropyrrolyl and morpholinyl derivatives of Virosaine A in anti-rhinitis medicines | |
| CN106074526A (en) | The composition of Schiglautone A derivative is used for preparing anti-rhinitis medicament thing | |
| CN105434413A (en) | Composition and application thereof to anti-rhinitis medicine | |
| CN105343099A (en) | Composition and application thereof in anti-rhinitis drug | |
| CN106420749A (en) | Application of composition of diethylamino and piperazinyl derivatives of Harrisotone A in anti-rhinitis medicine | |
| CN105287557A (en) | Composition and application thereof to rhinitis resistant medicines | |
| CN105796561A (en) | Application of composition of piperazine-based and imidazole-based derivatives of virosaine A in rhinitis-resistant medicine | |
| CN105343091A (en) | Composition and application thereof in rhinitis resistant drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161026 |
|
| WD01 | Invention patent application deemed withdrawn after publication |